Sarepta Therapeutics (SRPT) Income towards Parent Company (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Income towards Parent Company of $331.0 million for Q1 2026, up 173.96% year-over-year from $120.8 million in Q1 2025, and up 217.0% quarter-over-quarter from -$282.9 million in Q4 2025.
Sarepta Therapeutics (SRPT) Income towards Parent Company (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at $331.0 million for Q1 2026.
- In Q1 2026, Income towards Parent Company rose 173.96% year-over-year to $331.0 million; the TTM figure through Mar 2026 stood at $65.1 million (up 126.21% YoY), while the FY2025 annual figure was -$713.4 million, down 403.59% from the prior year.
- Income towards Parent Company for Q1 2026 stood at $331.0 million, up from -$282.9 million in the prior quarter.
- The five-year high for Income towards Parent Company was $331.0 million in Q1 2026, with the low at -$516.8 million in Q1 2023.
- The 5-year median for Income towards Parent Company is -$23.9 million (2023), against an average of -$55.7 million.
- Peak annual rise in Income towards Parent Company reached 2796.15% in 2025, while the deepest fall reached 1324.47% in 2025.
- Sarepta Therapeutics' Income towards Parent Company stood at $329.3 million in 2022, then tumbled by 86.19% to $45.5 million in 2023, then surged by 249.09% to $158.8 million in 2024, then sank by 278.14% to -$282.9 million in 2025, then soared by 217.0% to $331.0 million in 2026.
- Business Quant data shows SRPT's Income towards Parent Company at $331.0 million in Q1 2026, -$282.9 million in Q4 2025, and -$179.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.89 Mn |
| Mar 31, 2026 | 330.97 Mn |
| Dec 31, 2025 | -282.88 Mn |
| Sep 30, 2025 | -179.95 Mn |
| Jun 30, 2025 | 196.94 Mn |
| Mar 31, 2025 | -447.52 Mn |
| Dec 31, 2024 | 158.80 Mn |
| Sep 30, 2024 | 33.61 Mn |
| Jun 30, 2024 | 6.80 Mn |
| Mar 31, 2024 | 36.55 Mn |
| Dec 31, 2023 | 45.49 Mn |
| Sep 30, 2023 | -40.94 Mn |
| Jun 30, 2023 | -23.94 Mn |
| Mar 31, 2023 | -516.76 Mn |
| Dec 31, 2022 | 329.34 Mn |
| Sep 30, 2022 | -257.74 Mn |
| Jun 30, 2022 | -231.48 Mn |
| Mar 31, 2022 | -105.03 Mn |
| Dec 31, 2021 | -122.29 Mn |
| Sep 30, 2021 | -48.14 Mn |